1 We have previously found that human chymase cleaves big endothelins (ETs) at the Tyr 31 -Gly 32 bond and produces 31-amino acid ETs (1-31), without any further degradation products. In this study, we investigated the eect of synthetic ET-1 (1-31) on the proliferation of cultured human coronary artery smooth muscle cells (HCASMCs). 2 ET-1 (1-31) increased [ 3 H]-thymidine incorporation and cell numbers to a similar extent as ET-1 at 100 nM. This ET-1 (1-31)-induced [ 3 H]-thymidine uptake was not aected by phosphoramidon, an inhibitor of ET-converting enzyme. It was, however, inhibited by BQ123, an endothelin ET A receptor antagonist, but not by BQ788, an endothelin ET B receptor antagonist.
Introduction
Endothelin-1 (ET-1) is a 21-amino acid polypeptide which exhibits various physiological actions, such as vascular contraction (Yanagisawa et al., 1988) , cardiac hypertrophy (Arai et al., 1995) and mitogenesis (Chua et al., 1992) . Human ET-1 is generated from the 38-amino acid precursor, big ET-1, through cleavage of the Trp 21 -Val 22 bond via the action of a membrane-bound metalloprotease, ET-converting enzyme (ECE) (Shimada et al., 1994) . Although ECE was originally shown to be a membrane-bound metalloprotease (Shimada et al., 1994) , several other metalloproteases have also been postulated to catalyze the formation of ET-1 from big ET-1 (Matsumura et al., 1990) . Rat mast cell chymase has also been reported as a putative converter of big ET-1 to ET-1 (Wypij et al., 1992) .
We have recently found that human mast cell chymase, unlike rat mast cell chymases, selectively cleaves big ETs at the Tyr 31 -Gly 32 bond to produce novel trachea-constricting 31amino acid ETs, ETs (1-31), without any further degradation products . has been shown to cause contraction of rabbit aerent arterioles (Tamaki et al., 1997) as well as to cause an increase in intracellular free Ca 2+ concentration in human coronary artery smooth muscle cells (HCASMCs) (Yoshizumi et al., 1998) . Furthermore, ETs (1-31) have been isolated from various human organs, such as lung and heart (Okishima et al., manuscript in preparation) .
Chymase has been suggested to play a role in human atherosclerosis because chymase-containing mast cells were found to be rich in atherosclerotic plaques of human carotid arteries (Jeziorska et al., 1997) . Moreover, it has been reported that chymase reduces the cholesterol eux-inducing ability of serum which may promote atherogenesis (Lindstedt et al., 1996) . Although these studies suggest the involvement of chymase in atherosclerosis, the key molecule which directly relates to atherogenesis has not yet been elucidated. ET-1 (1-31) may be a candidate for this substance. Since ET-1 has been shown to cause proliferation of vascular smooth muscle cells (VSMCs) (Chua et al., 1992; Janakidevi et al., 1992; Kanse et al., 1995) , we hypothesized that ET-1 (1-31) is an alternative mitogen for VSMCs and relevant to atherogenesis.
In the present study, we examined the eect of synthetic ET-1 (1-31) on cultured HCASMC proliferation. Results suggest that induces HCASMC proliferation and is almost equipotent to ET-1. Furthermore, ET-1 (1-31) activates extracellular signal-regulated kinases (ERKs) belonging to a subfamily of the mitogen-activated protein kinase (MAPK) family (Davis, 1993; Nishida & Gotoh, 1993) . ET-1 (1-31) also activates DNA binding of activator protein-1 (AP-1) from HCASMC nuclear extracts.
Methods

Cell preparation and culture
Human coronary artery smooth muscle cells (HCASMCs) at passage 4 were obtained as a commercially available product from Clonetics Corp. (San Diego, CA, U.S.A.). Cells were plated in 25-cm 2 tissue culture¯asks at a density of 5610 3 cells cm 72 in MCDB131 medium supplemented with 5% heat-inactivated fetal calf serum, 0.5 ng ml 71 epidermal growth factor, 1 ng ml 71 basic ®broblast growth factor, 5 mg ml 71 insulin, 50 mg ml 71 gentamicin, and 0.25 mg ml 71 amphotericin B. The cells were incubated at 378C in 5% CO 2 and the medium was replaced every other day until the cells were 60 ± 80% con¯uent. The cells were then removed from the¯asks with 0.025% trypsin plus 0.01% EDTA and seeded onto 24-well culture plates (Coster Corp., Cambridge, MA, U.S.A.) for experiments of [ 3 H]-thymidine incorporation and cell counting. For experiments of in-gel kinase assay or gel mobility shift assay, the cells were seeded onto 35-mm or 100-mm tissue culture dishes (Coster Corp.), respectively. All experiments were performed with the cells in passage 5 ± 15 and at 1 ± 2 days post-con¯uency except for cell counting.
Determination of [ 3 H]-thymidine incorporation
Con¯uent HCASMCs in 24-well culture plates were made quiescent by placing them in serum-free medium supplemented with insulin (1 mM) and transferrin (5 mg ml 71 ) for 2 days. They were then stimulated for 24 h with 100 nM ET-1 (1-31) or ET-1. The stimulated cells were pulsed with 1 mCi ml 71 [ 3 H]-thymidine during the last 8 h of culture. Cells were washed once with PBS, and twice with ice-cold 5% trichloroacetic acid (TCA) to remove the unincorporated [ 3 H]-thymidine, then solubilized in 100 ml 0.25 N NaOH in 0.1% SDS and neutralized. Aliquots of samples were added to 10 ml of scintillation¯uid and counted (Aloka 703, Tokyo, Japan).
Determination of cell number
Subcon¯uent HCASMCs in 24-well culture plates were made quiescent by placing them in serum-free medium supplemented with insulin (1 mM) and transferrin (5 mg ml 71 ) for 2 days. Mitogenic stimulation of HCASMCs was performed as for [ 3 H]-thymidine uptake. Cell numbers were determined at indicated time points. Monolayers were washed twice in PBS, and HCASMCs were trypsinized for 20 min at 378C and transferred into 10 ml of MCDB131 medium for counting in a Coulter counter (Coulter Electronics, Krefeld, Germany). For each value, three wells were counted twice.
Protein extraction for protein kinase assay
Con¯uent HCASMCs in 35-mm tissue culture dishes were made quiescent by placing them in serum-free medium supplemented with insulin (1 mM) and transferrin (5 mg ml 71 ) for 2 days and harvested after stimulation with ET-1 (1-31) or ET-1 at indicated time points in 100 ml lysis buer (20 mM HEPES (pH 7.2), 25 mM NaCl, 2 mM EGTA, 50 mM NaF, 1 mM Na 3 VO 4 , 25 mM b-glycerophosphate, 0.2 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl¯uoride (PMSF), 60 mg ml 71 aprotinin, 2 mg ml 71 leupeptin, and 0.1% Triton X-100). After incubation at 48C for 30 min, the samples of HCASMC protein extract were sonicated (SONIFIER 250, Branson Ultrasonics Co., Danbury, U.S.A.) on ice for 1 min, and centrifuged at 10,0006g at 48C for 30 min. The protein concentrations of the supernatants were measured with a protein assay kit (PIERCE) and stored at 7808C until protein kinase assay.
Measurement of ERK activity in HCASMCs
The assay of ERK activity was performed using an in-gel kinase method as described (Kim et al., 1997; . Myelin basic protein (MBP) was used as ERK substrate. The samples of protein extracts (10 mg), prepared as described above, were boiled for 5 min in Laemmli sample buer, and electrophoresed on SDS-polyacrylamide (12%) gels polymerized in the presence of 0.5 mg ml 71 of MBP. After electrophoresis, SDS was removed by incubation in 50 mM Tris-HCl (pH 8.0) containing 20% isopropanol for 1 h. The gels were then washed with 5 mM b-mercaptoethanol in 50 mM Tris-HCl (pH 8.0) for 1 h. To denature the protein, gels were incubated in 50 mM Tris-HCl (pH 8.0) containing 6 M guanidine-HCl and 5 mM b-mercaptoethanol for 1 h. Proteins were then renatured by incubation in 50 mM Tris-HCl (pH 8.0) containing 0.04% Tween-40 and 5 mM bmercaptoethanol at 48C for 12 h. To measure the ability for phosphorylation of MBP, gels were equilibrated for 1 h in kinase buer (40 mM HEPES (pH 7.5), 0.1 mM EGTA, 20 mM MgCl 2 , and 2 mM DTT), and then incubated at 258C for 1 h in kinase buer with 25 mM adenosine triphosphate (ATP) and 25 mCi [g-32 P]ATP. Finally, the gels were washed extensively in 5% TCA and 1% sodium pyrophosphate several times and subjected to autoradiography. To estimate the phosphorylation of MBP, we digitized autoradiograms and measured their densities by using a bioimaging analyser (BAS-2000, Fuji photo ®lm Co., Tokyo, Japan).
Western blot analysis
By using rabbit polyclonal ERK antibodies (polyclonal rabbit anti-ERK1 (p44ERK) IgG (c-16); polyclonal rabbit anti-ERK2 (p42ERK) IgG (c-14)), we measured ERK proteins in HCASMCs with Western blot analysis as described previously . All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). HCASMC protein extract (10 mg protein), prepared as described above, were boiled for 5 min in Laemmli sample buer, then electrophoresed on a SDS polyacrylamide gel (12%), and the separated proteins were electrophoretically transferred to Hybond-PVDF membranes (Amersham, Buckinghamshire, U.K.). Complete protein transfer to the membrane was ensured by staining the gels with Coommasie Blue. Non-speci®c background was blocked by incubating the membrane with 5% bovine serum albumin in Tris-buered saline (pH 7.6) containing 0.1% Tween 20 (TBS-T) at 48C overnight. The membrane was then incubated with speci®c ERK1 and ERK2 antibodies (1 : 3000 dilution) for 1 h at room temperature, washed four times with TBS-T, and then incubated with horseradish peroxidase-conjugated donkey anti-rabbit immunoglobulin (Amersham, U.K.) at a dilution of 1 : 5000 in TBS-T. After a further washing with TBS-T, the membrane was treated with ECL reagent (Amersham, U.K.), and chemiluminescence was detected by exposure to Hyper®lm-ECL. The intensity of the bands was measured by Macintosh LC-III computer with an optical scanner (EPSON GT-8000, Seiko, Tokyo, Japan), using the public domain NIH Image program.
Gel mobility shift assay
For gel mobility shift assay, nuclear protein extracts were prepared from HCASMCs in 100-mm dishes after stimulation with ET-1 (1-31) or ET-1 at indicated time points. The samples were homogenized in 0.4 ml of 20 mM HEPES (pH 7.9) containing 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl 2 , 20% glycerol, 10 mM NaF, 1 mM Na 3 VO 4 , 0.2 mM DTT, 20 mM b-glycerophosphate, 0.5 mM PMSF, 60 mg ml 71 aprotinin, and 2 mg ml 71 leupeptin, incubated on ice for 15 min, and centrifuged at 15,000 r.p.m. at 48C for 10 min. The resulting supernatant was assayed for protein concentrations and stored at 7808C until use. The procedure for gel mobility shift assay has been described previously Hamaguchi et al., 1998) . In brief, gel mobility shift assay of HCASMC nuclear AP-1 binding activity was performed with an oligonucleotide probe containing the AP-1 binding sequence (5'-CGCTTGATGACTCAGCCGGAA-3') (Lee et al., 1987) . The probe was end-labeled with [g-32 P] ATP using T4 polynucleotide kinase, and puri®ed by chromatography on a Bio-Spin column (Bio-Rad, Hercules, CA U.S.A.). For DNA-protein-binding reaction, the samples of HCASMC nuclear protein extract (10 mg protein) were incubated with 10 fmol of a 32 P-labeled oligonucleotide containing the consensus AP-1 binding site at room temperature for 20 min, in 20 ml of binding buer consisting of 20 mM HEPES (pH 7.9), 0.2 mM EDTA, 0.2 mM EGTA, 80 mM NaCl, 0.3 mM MgCl 2 , 1 mM DTT, 0.2 mM PMSF, 6% glycerol, and 2 mg of polydeoxyinosinic-deoxycytidylic acid (poly[dI-dC]; Pharmacia Biotech, Uppsala, Sweden) as a nonspeci®c competitor. The DNA-protein complexes were separated from free DNA probe by electrophoresis on 4% nondenaturing polyacrylamide gels in 6.7 mM Tris-HCl (pH 7.5), 3.3 mM sodium acetate, 0.1 mM EDTA, and 2.5% glycerol. Gels were run at 200 V at 48C for 3 h, dried, subjected to autoradiography and analysed with a bioimaging analyser (BAS-2000) .
To demonstrate the speci®city of DNA-protein binding, binding reactions were performed as described above, in the presence of a 10, 50, 100 or 200 fold molar excess of a nonlabeled AP-1 consensus oligonucleotide competitor or 200 fold excess of a non-labeled mutant AP-1 oligonucleotide competitor (5'-CGCTTGATGACTTGGCCGGAA-3'), and followed by electrophoresis. Furthermore, to examine the possible contribution of c-Fos or c-Jun to speci®c AP-1 binding activity, supershift assays were performed with rabbit polyclonal anti-c-Fos IgG raised against amino acids 128 ± 152 of c-Fos and rabbit anti-c-Jun IgG raised against amino acids 247 ± 263 of c-Jun (Santa Cruz Biotechnology). Anti-c-Fos IgG or anti-c-Jun IgG (each 1 mg) was added to samples after the initial binding reaction between arterial protein extracts and 32 P-labeled consensus AP-1 oligonucleotide, the reaction was allowed to proceed at room temperature for 1 h and then the samples were subjected to electrophoresis, as described above.
Materials
Human ET-1 and phosphoramidon (N-(a-Rhamnopyranosyloxyhydroxyphosphinyl)-L-Leucyl-L-Tryptophan) were obtained from Peptide Institute (Osaka, Japan). ET-1 (1-31) was synthesized by solid-phase procedures at Peptide Institute. BQ123 (Cyclo-(D-Trp-D-Asp(ONa)-Pro-D-Val-Leu-)) and BQ788 (N-cis-2,6-dimethylpiperidinocarbonyl-L-gMeLeu-D-Trp(COOMe)-D-Nle-ONa) were gifts from Banyu Pharmaceutical Co. (Tsukuba, Japan). [g-32 P]ATP (10 mCi mmol 71 ) was from Amersham. Phorbol 12-myristate 13-acetate (PMA), staurosporine, genistein, and PD98059 were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). All other chemicals used were commercial products of reagent grade.
Statistics
Data are presented as means+s.e.mean for three to ®ve separate experiments. One-way analysis of variance was used to determine signi®cance among groups, after which the modi®ed t-test with the Bonferroni correction was used for comparison between individual groups. A value of P50.05 was considered to be statistically signi®cant.
Results
ET-1 (1-31) induced proliferation of HCASMCs similar to ET-1
Initial studies were performed to obtain information on the mitogenic eect and concentration-responses of ET-1 (1-31) on HCASMCs relative to ET-1. As shown in Figure 1 , ET-1 (1-31) caused an increase in [ 3 H]-thymidine incorporation into the cells in a concentration-dependent manner (100 pM to 1 mM). This eect of ET-1 (1-31) on HCASMCs DNA synthesis was similar to that of ET-1. To determine whether the eect of ET-1 (1-31) is a receptor-mediated phenomenon, we examined the eects of ET receptor antagonists on the increase in [ 3 H]thymidine incorporation evoked by ET-1 (1-31). Since it has been reported that there are at least two main subtypes of ET receptors, termed A-type (ET A ) and B-type (ET B ) of receptors (Watanabe et al., 1989) , we examined the eects of a speci®c ET A receptor antagonist, BQ123 (Ihara et al., 1992) , and a speci®c ET B receptor antagonist, BQ788 (Ishikawa et al., 1994) , on the ET-1 (1-31)-induced increase in DNA synthesis. The ET-1 (1-31)-induced increase in [ 3 H]-thymidine uptake was inhibited by 100 nM BQ123, but not by 100 nM BQ788 (Figure 2 ). Next, to investigate the possibility that the eect of ET-1 (1-31) is due to further degradation of ET-1 (1-31) to ET-1 by ECE in the medium or in the cells, we examined the eect of an inhibitor of ECE, phosphoramidon (Matsumura et al., 1991) , on the ET-1 (1-31)-induced increase in [ 3 H]-thymidine uptake. The increase in [ 3 H]-thymidine uptake evoked by ET-1 (1-31) was not aected by 1 mM phosphoramidon ( Figure 2 ). Counts of HCASMCs incubated with ET-1 (1-31) (100 nM) or ET-1 (100 nM) were determined on days 1, 3 and 5 after stimulation (Figure 3 ). ET-1 (1-31) led to a 1.54 fold increase in the HCASMC count on day 5 which was similar in extent to the eect of ET-1 at the same concentration. This roughly correlated with the results of DNA synthesis (Figures 1 and 3) .
Time course of ERK activity in HCASMCs after ET-1 (1-31) stimulation
As indicated by the autoradiograms in Figure 4 , ERKs in HCASMCs were composed of two isoforms, ERK1 (p44ERK) and ERK2 (p42ERK). After stimulation by ET-1 (1-31), ERK1 and ERK2 activities rapidly increased by 6.88 and 6.56 fold (P50.05), respectively, at 5 min and peaked (7.28 and 7.15 fold, respectively; P50.05) at 10 min ( Figure 4A) . Thereafter, the activities of both ERKs rapidly declined, returning to the baseline control value at 60 min after stimulation. The time course for the ERK activation induced by ET-1 was similar to that by ET-1 (1-31) ( Figure 4B ).
Concentration-response curve for ET-1 (1-31)-induced ERK activation in HCASMCs
We next examined ERK activation at dierent concentrations of ET-1 (1-31) by using the time points of maximum response for ERKs (10 min) and compared it to that of ET-1. As shown in Figure 5A , ET-1 (1-31) caused an increase in ERK activity in a concentration-dependent manner (from 100 pM to 1 mM). The concentration-response curve for ERK activation induced by ET-1 was compatible to that induced by ET-1 (1-31) ( Figure 5B) . These results are similar to the results of DNA synthesis evoked by ET-1 (1-31) and ET-1 (Figures 1 and 5 ).
Eects of PKC inhibition, MEK inhibition and tyrosine kinase inhibition on ET-1 (1-31)-induced ERK activation
To investigate the involvement of PKC in ET-1 (1-31)-induced ERK activation, the eects of staurosporine, as a PKC inhibitor, and downregulation of PKC by pretreatment with PMA for 24 h were examined. As shown in Figure 6 , 1 mM staurosporine or 100 nM pretreatment by PMA strongly inhibited the ET-1 (1-31)-induced ERK activation. PD98059 at 50 mM, a selective inhibitor of MAPK kinase or ERK kinase (MEK) which activates ERKs by phosphorylation on both threonine and tyrosine residues, also inhibited the ERK activation induced by ET-1 (1-31). However, pretreatment with genistein at 10 mM, a chemical inhibitor of tyrosine kinase, had little eect on ET-1 (1-31)-induced ERK activation. Figure 7 shows DNA binding activities of AP-1 from the nuclear extracts of HCASMCs after 2 h treatment with 100 nM ET-1 (1-31) or ET-1. As shown in the left panel of Figure 7A , the incubation of consensus AP-1 oligonucleotide with HCASMC nuclear extracts resulted in the formation of the broad shift band of AP-1 complexes. This shifted band was found to have speci®c binding for AP-1, because the addition of unlabeled AP-1 consensus oligonucleotide resulted in a decrease in the formation of AP-1 complexes in a concentration-dependent manner, but the addition of excess amounts of unlabeled mutant AP-1 oligonucleotide did not aect the AP-1 complexes. Furthermore, the addition of anti-c-Fos antibody and anti-c-Jun antibody, to the binding reaction produced supershifted complexes. As shown in Figure 7B , ET-1 (1-31) treatment for 2 h increased AP-1 binding activity in HCASMCs by 1.63 fold compared with the control. This increase in AP-1 DNA binding activity by ET-1 (1-31) was almost equipotent to that by ET-1. Moreover, the ET-1 (1-31)induced increase in AP-1 binding activity was inhibited by coincubation with 100 nM BQ123, as well as with 1 mM staurosporine or 50 mM PD98059, but not with 100 nM BQ788 ( Figure 7B ).
Eect of ET-1 (1-31) on DNA binding activity of AP-1 from HCASMCs
Discussion
We have previously found that human mast cell chymase speci®cally converts big ETs to novel vasoactive 31-amino acid peptides, ETs (1-31), which are longer than the well-known 21amino acid ETs . It has also been reported that a serine protease in human lungs hydrolyzes big ET-1 to a fragment of ET-1 (1-31) which has contractile activity in pulmonary artery (Hanson et al., 1997) . We also found that ET-1 (1-31) contracted rabbit aerent arterioles (Tamaki et al., 1997) or increased the intracellular free Ca 2+ concentration in HCASMCs (Yoshizumi et al., 1998) .
Recent accumulating evidence has revealed a pathophysiological role for chymase which relates to atherosclerosis (Jeziorska et al., 1997; Lindstedt et al., 1996) . It has been reported that chymase-containing mast cells accumulate in the shoulder region of coronary atheromas and this may be a trigger for atheromatous rapture (Kaartinen et al., 1994) . In addition, in®ltration by mast cells of the ruptured site of coronary atheromas has been observed in patients who died of myocardial infarction (Kovanen et al., 1995) . These studies suggest a role for human mast cell chymase in atherosclerosis. However, the underlying mechanism which results in chymaserelated atherogenesis has not been clari®ed. Since ET-1 has been suggested to play a role in the pathogenesis of atherosclerosis (Chua et al., 1992; Weissberg et al., 1990; Komuro et al., 1989) , ET-1 (1-31), produced by human mast cell chymase, may also be involved. Therefore, we investigated the eect of synthetic ET-1 (1-31) on HCASMC proliferation leading to atherosclerosis.
As shown in Figure 1 , the results revealed that the activity of ET-1 (1-31) to promote DNA synthesis in HCASMCs was almost equivalent to that of ET-1. Moreover, ET-1 (1-31) stimulated cell proliferation at 3 ± 5 days incubation similar to ET-1 (Figure 3) . These results suggest that ET-1 (1-31) has a potency to induce cell growth as well as ET-1. It is important to elucidate whether the eect of ET-1 (1-31) on HCASMCs is a result of its extracellular conversion to ET-1, or whether ET-1 (1-31) itself acts directly on the cells. As shown in Figure 2 , phosphoramidon, an inhibitor of metalloendopeptidases and ECE (Matsumura et al., 1991) , at a concentration of 1 mM had almost no eect on the increase in [ 3 H]-thymidine incorporation elicited by ET-1 (1-31), although phosphoramidon at the same concentration eectively inhibits the proliferating activity of big ET-1 (data not shown). These results are consistent with the ®ndings in the previous report that ECE requires the Cterminal structure of big ET-1 for enzyme recognition and is not able to cleave ET-1 (1-31) (Xu et al., 1994) . Taken together, the results indicate that the activity of ET-1 (1-31) to facilitate DNA synthesis is not a consequence of its conversion to ET-1 by ECE or metalloendopeptidase(s). It should be noted that ET-1 (1-31) itself has biological activity in HCASMCs, regardless of whether or not it is degraded to ET-1.
The above ®ndings surmise the hypothesis that ET-1 (1-31) binds to its receptor(s) without further proteolytic degradation and induces a proliferation of HCASMCs. As shown in Figure  2 , the cell proliferating eect of ET-1 (1-31) was inhibited by 100 nM of BQ123, but not by 100 nM of BQ788, known inhibitors of ET A and ET B receptors, respectively. Although we have no evidence that the receptor of ET-1 (1-31) is identical to that of ET-1, the results suggest that the cell response induced by ET-1 (1-31) is mediated through ET A or ET A -like receptors. Further studies are needed to clarify what types of receptors are involved in the ET-1 (1-31)-induced phenomenon.
The intracellular signal transduction pathways activated by ET receptors have been investigated. ETs have been shown to cause an increase in inositol 1,4,5-trisphosphate production (Xuan et al., 1994) , to mobilize Ca 2+ from intracellular and extracellular sources (Gardner et al., 1992) , and to activate protein kinase C (Griendling et al., 1989) in VSMCs. In mitogenesis, accumulating evidence shows that the activation of ERKs, belonging to the MAPK family, plays a critical role in the proliferation of a variety of cells induced by ET-1 (Cazaubon et al., 1993; Wang et al., 1994; Cadwallader et al., 1997) . However, to our knowledge, there have been no reports concerning the eect of ET-1 on ERKs in HCASMCs. Therefore, we investigated the eect of ET-1 (1-31) on ERK activity in HCASMCs and compared it to that of ET-1. As shown in Figure 4A , application of to HCASMCs resulted in a rapid and signi®cant activation of ERK1 and ERK2. It should be noted that the potency of ET-1 (1-31) in activating ERKs was similar to that of ET-1 ( Figure 5 ). In our previous studies, ET-1 (1-31) was ten times less potent than ET-1 in tracheal smooth muscle constriction and in increasing the intracellular free Ca 2+ concentration of HCASMCs (Yoshizumi et al., 1998) . One explanation for the discrepancy in the potencies of ET-1 (1-31) and ET-1 between our previous and present studies, is the existence of speci®c receptor(s) for . In any way, the potency of ET-1 (1-31) as a mitogen for HCASMCs is more notable than its ability as a vasoconstrictor.
Next, the signaling cascade from the extracellular stimuli to intracellular response induced by in HCASMCs was examined. A lot of information has been accumulated suggesting that the ET signal transduction pathway leading to ERK activation requires PKC, since depletion of PKC signi®cantly inhibited ERK activation stimulated by ET (Malarkey et al., 1995) . Our results shown in Figure 6 also revealed that ET-1 (1-31)-induced ERK activation was dependent on PKC because PKC-depletion by 24 h of PMA treatment (100 nM) or pharmacological PKC inhibition by staurosporine (1 mM) signi®cantly inhibited it. Other kinds of protein kinases known to be involved in mitogenesis, such as tyrosine kinases, would relate little to ERK activation by ET-1 (1-31), since the well known tyrosine kinase inhibitor genistein (10 mM) inhibited less ERK activation by ET-1 (1-31) than staurosporine ( Figure 6 ). It has been indicated that ERKs are activated by MEK, which exist just upstream of the signal transduction cascade of ERK activation, by phosphorylation on both threonine and tyrosine residues of ERKs (Crews et al., 1992) . Therefore, we examined the eect of the selective MEK inhibitor, PD98059 (Servant et al., 1996) on ET-1 (1-31)induced ERK activation. As shown in Figure 6 , pretreatment with 50 mM PD98059 signi®cantly inhibited the activation. These results are consistent with the notion that MEK activity directly relates to the activation. However, mechanisms other than ERK activation cannot be ruled out because PKC inhibition and MEK inhibition both failed to complete suppression of ET-1 (1-31)-induced ERK activation. Further studies are needed to clarify the intracellular signaling pathway leading to cell proliferation induced by .
It is believed that ERKs play a central role in the formation of transcription factor AP-1 complex (Karin, 1995) . ERKs are known to induce c-fos mRNA expression by phosphorylating Elk-1/TCF transcription factors (Karin, 1995) . Previously, ET-1 treatment has been shown to increase c-fos or c-jun mRNA in various cell types (Komuro et al., 1989; Simonson et al., 1992) . Therefore, we examined the eect of ET-1 (1-31) on AP-1 DNA binding activity in HCASMCs as well as ET-1. Our present study, using gel shift analysis, provided the ®rst evidence that AP-1 DNA binding activity, which contains c-Fos and c-Jun proteins, signi®cantly increased on the addition of ET-1 (1-31) as well as ET-1 (Figure 7) . The present ®nding is consistent with a report that ET-1 stimulates AP-1 DNA binding activity in rat mesangial cells (Simonson & Herman, 1993) . Thus, it is likely that the activation of AP-1 is implicated in the stimulation of HCASMC growth by ET-1 (1-31).
Our present data on gel shift analysis of AP-1 activity demonstrates that the inhibition of ET A or ET A -like receptors, as well as the inhibition of PKC or MEK, is associated with the suppression of activation of AP-1 complex ( Figure 7B ). These ®ndings suggest that the suppression of AP-1 activity by ET A receptor antagonist is at least in part mediated by the suppression of ERK activation and that ERKs are responsible for AP-1 activation in HCASMCs, although the present work provided no direct evidence of this.
In conclusion, ET-1 (1-31) is a novel putative vasoactive peptide of the ET family that may be deeply involved in chymase-related pathophysiological processes in humans. We obtained the ®rst evidence that ET-1 (1-31) is equipotent to ET-1 in HCASMC proliferation. The intracellular signal transduction cascade induced by ET-1 (1-31) may be explained in part by PKC-dependent activation of ERKs, a main A competition assay for AP-1 was carried out in the presence of a 10-, 50-, 100-and 200 fold molar excess of unlabeled AP-1 oligonucleotide (competitor) or unlabeled 200 fold molar excess of mutant AP-1 oligonucleotide (mutant). Supershift analysis was performed with speci®c anti-c-Fos and anti-c-Jun antibodies. (B) Eects of ET receptor antagonists, PKC inhibitor or MEK inhibitor on ET-1 (1-31)-induced increase in AP-1 DNA binding activity from HCASMC nuclear extracts. Bar graph shows HCASMC nuclear extracts AP-1 DNA binding activities stimulated with 100 nM ET-1 (1-31) or ET-1 for 2 h. For the experiments of the inhibitors against ET-1 (1-31)-induced increase in AP-1 DNA binding activity, BQ123 (100 nM), BQ788 (100 nM), staurosporine (1 mM), and PD98059 (50 mM) were added to the incubation medium 30 min prior to ET-1 (1-31) stimulation. The control value is the AP-1 DNA binding activity obtained without ET-1 (1-31) or ET-1 which is represented as 1. Each value is expressed as the mean+s.e.mean of three separate experiments. *P50.05 from the control value. **P50.05 from the value with 100 nM ET-1 (1-31).
subgroup of the MAPK family, which is associated with the activation of transcription factor AP-1 complex. The activation of ERKs by ET-1 (1-31) may be mediated by ET A or ET Alike receptors. Since chymase plays a signi®cant role in foam cell formation in human coronary atheromas (Kaartinen et al., 1994; Kovanen et al., 1995) , the pathogenesis of atherosclerosis in coronary artery may be partly attributable to the eect of bioactive ET derivatives, including ET-1 (1-31), an endogenous product of human mast cell chymase.
